adagrasib news

All news on adagrasib (also known as MRTX849 and Krazati): plants, production capacities, investments and involved companies.

2 July 2026

Roche: Divarasib outperforms first‑generation KRAS G12C inhibitors in phase III Krascendo 1

Head‑to‑head phase III in previously treated KRAS G12C NSCLC: divarasib improved progression‑free and overall survival versus sotorasib/adagrasib with a consistent safety profile.
1 July 2026

Genentech's divarasib outperforms approved KRAS G12C inhibitors in Phase III NSCLC trial

Head-to-head Phase III shows divarasib improves progression-free and overall survival versus sotorasib/adagrasib; safety consistent; data to be filed and presented.

Who will be producing adagrasib in the future?

Find out with chemXplore Alpha

Learn more